About Virovek, Inc.

World's most efficient large-scale AAV manufacturing system through our innovation and
proprietary technologies

Toxin-Based Cell Ablation

technology using AAV vectors as the delivery vehicle

Custom-Made AAV

vector production service from 1E+13vg scale to 3E+16vg scale
results may vary

Safety and Storage

handled in a Biosafety Level 1 (BSL-1) environment

Intermediate Products

sells intermediates from all points in our AAV Production process

Pre-Made AAVs

approximate default titer of 2 x
10^13 vg/mL

 

Specializing in large scale AAV Production

World's most efficient large-scale AAV manufacturing system through our innovation and
proprietary technologies

Promotions & Discounts

Special offer for all academic and non-profit organizations on Virovek's custom-made AAV vectors.

AAV Production Platform

Virovek's proprietary AAV vector production technology has revolutionized the field of AAV manufacturing. This technology is available for non-exclusive licensing.

Cell Ablation Platform

Virovek has developed the world's only AAV-toxin production platform for cell ablation research and therapy. This technology is also available for licensing.

Contract Manufacturing

Virovek's custom-made AAV vectors are consistently lauded as the best in the field.

Customer Testimonials

Virovek did a superb job of preparing several recombinant AAVs (rAAVs) for our animal and cell based studies. They were able to achieve viral titers well above anyone else. I look forward to further production of rAAVs from Virovek in the future.

Lee Henderson

Ph.D., CEO, Vybion Inc.

Thanks for all your help. The viral vectors you’ve made for us so far work great!

Scott Russo

Ph.D., Assistant Professor, Mount Sinai School of Medicine

You make the best AAV in the country, if not the world. That is a true statement.

Rachel Neve

Ph. D., Director of Viral Gene Transfer Core, MIT

Virovek News And Events

Bio-manufacturing and processing summit (ManuBio USA 2013)

Events

Bio-manufacturing and processing summit (ManuBio USA 2013)

June 10, 2013  gowranga

Discontinuation of Baculovirus Titration Kit, BacEZ Titer Kit

Events

Discontinuation of Baculovirus Titration Kit, BacEZ Titer Kit

June 3, 2013  gowranga

Virovek’s latest suicide gene therapy technology

Events

Virovek’s latest suicide gene therapy technology

April 12, 2013  gowranga

Newest patented technology to manufacture AAV vectors harboring toxins

Events

Newest patented technology to manufacture AAV vectors harboring…

January 7, 2013  gowranga

Avalanche Biotechnologies, Inc. and Lonza will use Virovek’s patented technology

Events

Avalanche Biotechnologies, Inc. and Lonza will use Virovek’s…

May 16, 2012  gowranga

Methods in Molecular Biology 737 — Viral Vector for Gene Therapy

Events

Methods in Molecular Biology 737 — Viral Vector…

June 10, 2011  gowranga

Virovek will cut cost for academic and non-profit organizations

Events

Virovek will cut cost for academic and non-profit…

November 20, 2009  gowranga

Virovek launched a new product, BacEZ Titer Kit

Events

Virovek launched a new product, BacEZ Titer Kit

April 10, 2009  gowranga

Artificial Intron: A New Tool to express Overlapping Genes

Events

Artificial Intron: A New Tool to express Overlapping…

January 12, 2009  gowranga

MIT will use Virovek’s AAV production technology

Events

MIT will use Virovek’s AAV production technology

January 7, 2009  gowranga

Intron splicing-mediated expression of AAV Rep and Cap genes

Events

Intron splicing-mediated expression of AAV Rep and Cap…

February 6, 2008  gowranga

Virovek launched a free AAV vector production program

Events

Virovek launched a free AAV vector production program

October 4, 2007  gowranga

MORE ARTICLES

Partners and Customers